Supernus Pharmaceuticals reported $111.49M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Ani Pharmaceuticals ANIP:US USD 56.28M 7.1M
Aurora Cannabis Inc ACB:CN CAD 369.28M 68.53M
Bristol Myers Squibb BMY:US USD 9.12B 1.39B
Canopy Growth Corp WEED:CN CAD 318.43M 6.29M
Cara Therapeutics CARA:US USD 42.81M 3.91M
Corcept Therapeutics CORT:US USD 50.24M 14.9M
Endo International Ordinary Shares ENDP:US USD 1.05B 137.68M
Horizon Pharma HZNP:US USD 2.13B 237.96M
Jazz Pharmaceuticals JAZZ:US USD 482.67M 191.74M
Lannett LCI:US USD 55.85M 22.07M
Marinus Pharmaceuticals MRNS:US USD 168.25M 75.92M
Pacira Pharmaceuticals PCRX:US USD 109.42M 12.64M
Perrigo Ordinary Shares PRGO:US USD 468.7M 16.6M
Revance Therapeutics RVNC:US USD 104.49M 35.07M
Supernus Pharmaceuticals SUPN:US USD 111.49M 61.94M
Teva Pharmaceutical Industries TEVA:US USD 2.22B 167M
United Therapeutics UTHR:US USD 966.8M 171.6M
Xeris Pharmaceuticals Inc XERS:US USD 84.11M 11.23M